#USA #Gainesville #Exactech #SVP #Stellex

Exactech's Restructuring Milestone: A New Era Begins

In a pivotal moment for the medical technology sector, Exactech, a renowned player in orthopedic solutions, has recently announced that it has identified a group of investors as the winning bidders to acquire the majority of its assets. This transformative step is part of Exactech's ongoing restructuring strategy, aimed at revitalizing its business and positioning it for future growth.

Key Details of the Bid

The winning investor group comprises two significant firms: Strategic Value Partners, LLC and Stellex Capital Management LLC. Together, these firms have an impressive portfolio, managing over $25 billion in assets and possessing deep operational insights into the medical technology landscape. Pending court approval, the sale is set to be finalized by late May, contingent on regulatory requirements.

Darin Johnson, President and CEO of Exactech, expressed enthusiasm about the new collaboration. He stated, “We are pleased that an investor group that recognizes our strengths and shares our commitment to high-quality medical devices has committed to moving forward with this acquisition. This partnership aims to enhance our ability to innovate and serve orthopedic surgeons and patients globally.”

The restructuring process, initiated several months prior, has not hindered Exactech’s commitment to delivering quality devices. In fact, it has reinforced the company's dedication to improving patient outcomes through innovative technologies.

Strengthening the Foundation

As part of the acquisition deal, the investor group has pledged over $100 million in additional financing. This capital infusion will be crucial for funding ongoing operations and solidifying Exactech’s market position. The focus remains clear: enhancing growth, innovation, and the delivery of superior products in the orthopedic field.

Clara Anderson, Managing Director at Strategic Value Partners, shared her excitement regarding the company's future, remarking, “Exactech has a rich history of innovation and a commitment to improving patient lives. Our focus is to capitalize on this legacy while fostering opportunities for further advancements.”

Engaging with the Surgical Community

Surgeons attending the AAOS 2025 Annual Meeting will have the opportunity to connect directly with representatives from the investor group and learn about Exactech's innovative solutions firsthand. Featuring a range of surgeon-focused technologies, including the AI-driven Active Intelligence® platform, Exactech aims to empower surgeons with tools designed for precision and enhanced patient outcomes.

Attendees will witness hands-on demonstrations of groundbreaking products like the ExactechGPS® navigation system, Predict+® patient-specific outcome predictor, and several innovations within the Equinoxe® Shoulder and Vantage® Total Ankle Systems. Exactech's latest polyethylene product, Activit-E®, will also be showcased, promising to improve surgical results and patient satisfaction.

A Bright Future Ahead

In a rapidly-evolving industry, Exactech’s strategic pivot towards a stronger financial footing and a focus on innovation sets the stage for a promising future. With the backing of seasoned investors, the company looks forward to embarking on new endeavors that will enhance its offerings and capitalize on existing partnerships within the medical community.

As Exactech readies itself to emerge from restructuring, its commitment to be the leading partner for orthopedic surgeons remains unwavering. The upcoming months will be critical for the company as it navigates this transition, ultimately aiming to deliver on its promise of excellence in patient care and surgical outcomes.

To stay updated on Exactech’s advancements and offerings, visit Exactech’s official website.